semaglutide gastric stasis class action in louisiana legal team glp-1 attorney glp-1 gastric stasis semaglutide gastric stasis class action – louisiana glp-1 gastric stasis class

The three most recent Phase 3 readouts are: TRIUMPH-4 (December 2025) showing 28.7% weight reduction at 68 weeks in obesity with knee osteoarthritis, TRANSCEND-T2D-1 (March 2026) showing A1C reductions up to 2.0% and 16.8% weight loss at 40 weeks in type 2 diabetes, and TRIUMPH-1 (May 2026) showing up to 25.0% weight reduction at 80 weeks in the pivotal obesity trial

Dec 20 2017;13(1):395

Additional in vitro evidence showed selenocysteine increased hepatic uptake of MeHg + as a Se-MeHg complex, and reduced cytotoxicity of the MeHg [Citation137]

These benefits were further supported by the results of the SUMMIT trial, which investigated tirzepatide, a dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist, in patients with HFpEF with or without T2D

The formulation targets users experiencing reduced food volume and low energy levels